To say January was a bleak month for Alzheimer’s research would be something of an understatement: Pfizer ducked out of the space and there were some significant drug failures.
That’s why the news that Japanese and Australian scientists have managed to develop a new means of early testing for the disease is being welcomed so strongly.
